This company has been marked as potentially delisted and may not be actively trading. NASDAQ:LMDX LumiraDx (LMDX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About LumiraDx Stock (NASDAQ:LMDX) 30 days 90 days 365 days Advanced Chart Get LumiraDx alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.0076▼$0.016052-Week Range N/AVolume132.24 million shsAverage Volume56.75 million shsMarket Capitalization$5.10 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewLumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care. The company has tests on the market and in development covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, as well as a portfolio of COVID-19 testing solutions. Its diagnostic testing solutions are deployed by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness, as well as disease. The company is headquartered in London, the United Kingdom.Read More… Receive LMDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for LumiraDx and its competitors with MarketBeat's FREE daily newsletter. Email Address LMDX Stock News HeadlinesFormer Alere and LumiraDx R&D Chief Nigel Lindner Joins CLEU Diagnostics to Launch Revolutionary LabSimple Diagnostic PlatformMarch 17, 2025 | businesswire.comLumiraDx Ltd LMDXFApril 14, 2024 | morningstar.comThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.April 21, 2025 | Paradigm Press (Ad)LMDX.OJanuary 31, 2024 | reuters.comWhy LumiraDx Shares Are Trading Lower By Over 30%; Here Are 20 Stocks Moving PremarketJanuary 8, 2024 | msn.comWhy Is LumiraDx (LMDX) Stock Down 13% Today?January 8, 2024 | investorplace.comLumiraDx Announces its Securities will be Suspended from Trading on Nasdaq at the Open of Business on January 9thJanuary 5, 2024 | finance.yahoo.comRoche (RHHBY) to Acquire LumiraDx's Point of Care TechnologyJanuary 2, 2024 | msn.comSee More Headlines LMDX Stock Analysis - Frequently Asked Questions How were LumiraDx's earnings last quarter? LumiraDx Limited (NASDAQ:LMDX) issued its quarterly earnings results on Thursday, August, 24th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.15) by $0.01. The company had revenue of $21 million for the quarter, compared to analysts' expectations of $21.07 million. What other stocks do shareholders of LumiraDx own? Based on aggregate information from My MarketBeat watchlists, some other companies that LumiraDx investors own include Predictive Oncology (POAI), Ford Motor (F), Bank of America (BAC), Abbott Laboratories (ABT), Wells Fargo & Company (WFC), JPMorgan Chase & Co. (JPM) and Wayfair (W). Company Calendar Last Earnings8/24/2023Today4/20/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:LMDX CIK1685428 Webwww.lumiradx.com Phone354-640-0540FaxN/AEmployees1,210Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-447,790,000.00 Net Margins-268.45% Pretax Margin-264.58% Return on EquityN/A Return on Assets-77.91% Debt Debt-to-Equity RatioN/A Current Ratio0.45 Quick Ratio0.23 Sales & Book Value Annual Sales$126.52 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($0.33) per share Price / BookN/AMiscellaneous Outstanding Shares318,546,000Free Float205,749,000Market Cap$5.10 million OptionableNot Optionable Beta1.73 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:LMDX) was last updated on 4/21/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredAmazon ShockerJeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LumiraDx Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share LumiraDx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.